You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新股消息 | 德琪醫藥向港交所遞表,富達、貝萊德、GIC、高瓴等持股

uSMART友信智投8月27日消息,生物醫藥公司赴港上市接踵而至,繼藥明巨諾-B、和鉑醫藥-B、百奧泰-B之後,近兩週遞表的重磅公司又添一家——德琪醫藥-B,高盛和摩根大通爲保薦人。

德琪醫藥是一家領先的亞太地區臨牀階段專注於創新抗腫瘤藥物的生物製藥公司,已建立12條強勁且具有高度創新性的臨牀及臨牀前產品研發管線。

核心產品之一ATG-010 (selinexor),或者XPOVIO® (selinexor)是一款同類第一及同類唯一的抑制核輸出蛋白XPO1的SINE化合物,可促使腫瘤抑制蛋白在細胞核內積累,選擇性誘導癌細胞凋亡。FDA已批準XPOVIO® (selinexor)用於治療復發╱難治性多發性骨髓瘤及復發╱難治性瀰漫性大B細胞淋巴瘤,並於2020年7月受理Karyopharm的補充NDA,作爲之前至少接受過1到3次治療的多發性骨髓瘤患者的治療方案。

德琪醫藥的股東陣容異常耀眼,醫藥行業的戰略投資者包括百時美施貴寶旗下的新基中國、藥明康德和泰格醫藥,國內外頂尖機構投資者包括富達、貝萊德、GIC、高瓴、博裕資本、方源資本、啓明創投泰康資管

近兩週已遞表及傳聞要赴港上市的重磅生物醫藥公司如下:

新股消息 | 藥明康德、淡馬錫投資的JW(Cayman)向港交所遞表

新股消息 | 奧博資本、GIC投資的和鉑醫藥向港交所遞表

新股消息 | 傳騰盛博藥最快明年首季赴港上市,紅杉資本、博裕資本系股東

此外,早前已在港交所遞表並有望於下半年招股的生物醫藥公司包括:

嘉和生物-B

未盈利的生物製藥公司,專注於腫瘤及自身免疫藥物的研發及商業化。高瓴資本爲第一大股東,淡馬錫等頂級機構亦有投資。保薦人:高盛、摩根大通、傑富瑞。

榮昌生物-B

未盈利的生物製藥公司,致力於自身免疫、腫瘤和眼科疾病的發現、開發及商業化,獲得奧博資本、清池資本、禮來亞洲基金等重磅機構加持。保薦人:摩根士丹利、華泰、摩根大通。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account